首页> 中文期刊> 《中国现代药物应用》 >造血干细胞移植治疗5例Wiskott-Aldrich综合征疗效分析

造血干细胞移植治疗5例Wiskott-Aldrich综合征疗效分析

         

摘要

ObjectiveTo analyze curative effect by hematopoietic stem cell transplantation in the treatment of Wiskott-Aldrich syndrome (WAS).Methods Long-term follow-up data of 5 WAS children patients who received allogene hematopoietic stem cell transplantation were retrospectively analyzed.ResultsAll 5 cases had hemopoietic reconstitution. There were 2 cases without acute graft versus host disease (aGVHD), 2 cases withⅠ~ⅡaGVHD, and 1 death case due to complicated hepatic venous obstructive disease (VOD) after transplantation. Mean follow-up time was 30 months in 4 cases, who were all in good health.Conclusion Hematopoietic stem cell transplantation can effectively treat WAS, prevent aGVHD and improve quality of life, along with long-term survival in patients.%目的:分析造血干细胞移植治疗Wiskott-Aldrich综合征(WAS)患儿的治疗效果。方法回顾分析接受异基因造血干细胞移植治疗的5例WAS患儿的长期随访资料。结果5例患儿均获得造血功能重建,2例未发生急性移植物抗宿主病(aGVHD),2例出现Ⅰ~Ⅱ度aGVHD,1例移植后合并肝静脉阻塞性疾病(VOD)死亡,4例平均随访时间30个月,目前健康状况良好。结论造血干细胞移植可有效治疗WAS,积极预防及治疗aGVHD,提高生存质量,可使患儿获得长期生存。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号